Ajmalicine

Revision as of 18:43, 27 September 2011 by WikiBot (talk | contribs) (Protected "Ajmalicine": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Ajmalicine
File:Ajmaline.svg
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC20H26N2O2
Molar mass326.433 g/mol

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Ajmaline is a class Ia antiarrhythmic agent. It is often used to bring out typical findings of ST elevations in patients suspected of having Brugada syndrome.

The compound was first isolated by Salimuzzaman Siddiqui in 1931 [1] from the roots of Rauwolfia serpentina. He named it Ajmaline, after Hakim Ajmal Khan, one of the most illustrious practitioners of Unani medicine in South Asia.[2]

Notes

  1. Siddiqui, S.; Siddiqui, R. H. (1931). J. Indian Chem. Soc. 8: 667–80.
  2. Ahmed Nasim Sandilvi (2003), Salimuzzaman Siddiqui: pioneer of scientific research in Pakistan. Daily Dawn. 12 April, 2003. Retrieved on 19 July 2007.


Template:Antiarrhythmic agents Template:Drug-stub

de:Ajmalin

Template:WS